Literature DB >> 6837839

Late metastatic Leishmaniasis in the mouse. A model for mucocutaneous disease.

A Barral, E A Petersen, D L Sacks, F A Neva.   

Abstract

BALB/c, C57B1/6 and (BALB/c x C57B1/6)F1 mice all proved susceptible to infection by a strain of Leishmania isolated from a Central Brazilian with espundia. The course of disease differed markedly between BALB/c and C57B1/6 mice. BALB/c mice suffered from a rapidly progressive and widely metastatic, but non-ulcerative, disease resembling diffuse cutaneous leishmaniasis. In contrast, C57B1/6 mice initially contained parasite multiplication effectively and appeared clinically cured. However, the parasite could persistently be cultured up to about 1 year post-infection. At that time, the parasite load in the infected footpad increased and a patent disease developed characterized by distinctive ulcerative metastases with destruction of soft-tissue in the nasal region similar to the one observed in espundia. Development of disease in both strains of mice was associated with depression of cell-mediated immunity as monitored by delayed-type hypersensitivity in vivo and lymphocyte transformation in vitro. Thus, our study suggests that diffuse cutaneous leishmaniasis and espundia can be caused by the same strain of parasite, and that the particular clinical expression in the individual mouse is determined by the host response.

Entities:  

Mesh:

Year:  1983        PMID: 6837839     DOI: 10.4269/ajtmh.1983.32.277

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  20 in total

1.  Characterization of cellular immune response to chemically defined glycoconjugates from Leishmania mexicana subsp. amazonensis.

Authors:  M M Rodrigues; M T Xavier; L M Previato; M A Barcinski
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

2.  Gene expression analysis of wild Leishmania major isolates: identification of genes preferentially expressed in amastigotes.

Authors:  Meriem Ouakad; Mehdi Chenik; Yosser Ben Achour-Chenik; Hechmi Louzir; Koussay Dellagi
Journal:  Parasitol Res       Date:  2006-10-03       Impact factor: 2.289

3.  Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes.

Authors:  M Barral-Netto; S G Reed; M Sadigursky; G Sonnenfeld
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

4.  Histopathologic changes induced by vaccination in experimental cutaneous leishmaniasis of BALB/c mice.

Authors:  M Barral-Netto; L A de Freitas; Z A Andrade
Journal:  Am J Pathol       Date:  1987-05       Impact factor: 4.307

5.  Characterization of an antigen from Leishmania amazonensis amastigotes able to elicit protective responses in a murine model.

Authors:  C G Beyrodt; A R Pinto; E Freymüller; C L Barbiéri
Journal:  Infect Immun       Date:  1997-06       Impact factor: 3.441

6.  CD4+ Th1 cells induced by dendritic cell-based immunotherapy in mice chronically infected with Leishmania amazonensis do not promote healing.

Authors:  Yannick F Vanloubbeeck; Amanda E Ramer; Fei Jie; Douglas E Jones
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

7.  Inbred strains derived from feral mice reveal new pathogenic mechanisms of experimental leishmaniasis due to Leishmania major.

Authors:  Besma E C Babay; Hechmi Louzir; Chahnaz Kebaïer; Samir Boubaker; Koussay Dellagi; Pierre-André Cazenave
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

8.  Membrane glycoprotein M-2 protects against Leishmania amazonensis infection.

Authors:  J Champsi; D McMahon-Pratt
Journal:  Infect Immun       Date:  1988-12       Impact factor: 3.441

9.  Immunopathology of experimental cutaneous leishmaniasis.

Authors:  Z A Andrade; S G Reed; S B Roters; M Sadigursky
Journal:  Am J Pathol       Date:  1984-01       Impact factor: 4.307

10.  Resistance to cutaneous leishmaniasis: acquired ability of the host to kill parasites at the site of infection.

Authors:  J O Hill
Journal:  Infect Immun       Date:  1984-07       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.